Lariago 40mg Injection contains Chloroquine, an antimalarial agent used primarily for the treatment and prophylaxis of malaria caused by Plasmodium species. Chloroquine exerts its therapeutic effect by interfering with the parasite's ability to digest hemoglobin, leading to toxic accumulation of heme within the parasite and subsequent death. This injectable formulation provides a rapid and effective route of administration, particularly useful in cases where oral intake is compromised or rapid drug action is required. Lariago 40mg Injection is indicated for acute attacks of malaria, including chloroquine-sensitive strains of Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. It may also be used for prophylaxis in endemic areas under medical supervision. Dosage and duration of therapy should be determined based on the severity of infection, patient weight, and clinical response. Caution is advised in patients with a history of hypersensitivity to chloroquine or related compounds, and in those with pre-existing retinal or visual field changes due to the risk of retinopathy with prolonged use. Common side effects include gastrointestinal disturbances, headache, dizziness, and pruritus. Lariago 40mg Injection should be administered under strict medical supervision with appropriate monitoring for adverse reactions and therapeutic efficacy.